The inclusion of oral phosphate lowering drugs in the dialysis payment bundle starting in January 2025 is a significant change that has sparked debates and discussions within the kidney community. Lori and Jeffrey Silberzweig, MD delve into this topic along with a brief history and evolution of the bundled payment system. They discuss the pros and cons of this action and potential limitations on medication choices for patients. While bundling care encourages healthcare providers to consider overall value and efficiency in their treatment approaches it can prevent individualized treatment plans for delivery of patient care.
Take action on current legislation regarding orals in the bundle:
Tell Congress to Support the Kidney PATIENT Act
Learn more about the dialysis bundle:
Infographic – What’s in the Dialysis Bundle?
Bio: Jeffrey Silberzweig, MD is the Chief Medical Officer of The Rogosin Institute, leads the dialysis programs at New York-Presbyterian Hospital as Chair of the Dialysis Executive Council and is the medical director of the dialysis units at the Weill Cornell and Lower Manhattan Hospital Campuses. He has been a nephrologist and leader in the community for over 25 years and has received many prestigious awards.
You can also listen to and download the podcast with these apps:
Hosted By Lori Hartwell
Lori Hartwell is the Founder & President of Renal Support Network (RSN) and the host of KidneyTalk®, a radio podcast show. Lori was diagnosed with kidney disease at the age of two. In 1993 she founded RSN to instill “health, happiness and hope” into the lives of those affected by chronic kidney disease. Lori is also the author of the inspirational book Chronically Happy: Joyful Living in Spite of Chronic Illness and is a four-time kidney transplant recipient.
Web ID 3128